Unknown

Dataset Information

0

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.

ABSTRACT:

SUBMITTER: Diaz LA 

PROVIDER: S-EPMC9533375 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.

Diaz Luis A LA   Shiu Kai-Keen KK   Kim Tae-Won TW   Jensen Benny Vittrup BV   Jensen Lars Henrik LH   Punt Cornelis C   Smith Denis D   Garcia-Carbonero Rocio R   Benavides Manuel M   Gibbs Peter P   de la Fourchardiere Christelle C   Rivera Fernando F   Elez Elena E   Le Dung T DT   Yoshino Takayuki T   Zhong Wen Yan WY   Fogelman David D   Marinello Patricia P   Andre Thierry T  

The Lancet. Oncology 20220412 5

<h4>Background</h4>Pembrolizumab has shown improved progression-free survival versus chemotherapy in patients with newly diagnosed microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. However, the treatment's effect on overall survival in this cohort of patients was unknown. Here, we present the final overall survival analysis of the KEYNOTE-177 study.<h4>Methods</h4>This randomised, open-label, phase 3 study was done in 193 academic medical centres and hosp  ...[more]